Literature DB >> 25434479

Protective effect of resveratrol against cisplatin-induced ototoxicity in HEI-OC1 auditory cells.

Se Hee Lee1, Hyung Sub Kim2, Yun Suk An3, Jiwon Chang4, June Choi5, Gi Jung Im6.   

Abstract

OBJECTIVES: Cisplatin is an effective chemotherapeutic drug, but it generates reactive oxygen species (ROS) that induce severe adverse effects such as ototoxicity. Resveratrol reportedly prevents oxidative stress-induced cell death. Thus, we hypothesized that the anti-oxidative effect of resveratrol could protect against cisplatin-induced ototoxicity. The present study examined the protective effect of resveratrol against cisplatin-induced ototoxicity in HEI-OC1 auditory cells.
METHODS: HEI-OC1 cells were pretreated with resveratrol at 1μM for 24h and then exposed to 15μM cisplatin for 48h. Resulting cytotoxicity was measured by the MTT method, and intracellular ROS was measured using flow cytometry. Protective effect of resveratrol was compared with other anti-oxidants.
RESULTS: Pretreatment with resveratrol 1μM protected HEI-OC1 auditory cells against cisplatin-induced cytotoxicity and significantly reduced a cisplatin-induced increase in ROS. Resveratrol provided significant protection against 15μM cisplatin applied for 48h (50.8% cell viability in the cisplatin group vs. 57.6% in the cisplatin-plus-resveratrol group), and there was a 9% decrease in cisplatin-induced ROS associated with resveratrol.
CONCLUSIONS: This is the study investigating the protective effects of resveratrol against cisplatin-induced ototoxicity in an auditory cell line. Resveratrol significantly reduced a cisplatin-induced increase in ROS and thereby inhibited cisplatin-induced cytotoxicity.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cisplatin; Ototoxicity; Reactive oxygen species; Resveratrol

Mesh:

Substances:

Year:  2014        PMID: 25434479     DOI: 10.1016/j.ijporl.2014.11.008

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  4 in total

1.  Prophylactic etanercept treatment in cisplatin ototoxicity.

Authors:  Sinem Dasli; Murat Topdag; Ahmet Mutlu; Ahmet Kara; Murat Ozturk
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-20       Impact factor: 2.503

2.  Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study.

Authors:  Gökçe Simsek; Burak Mustafa Taş; Nuray Bayar Muluk; Musa Azman; Rahmi Kılıç
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-17       Impact factor: 2.503

3.  Acquired sensorineural hearing loss in children: current research and therapeutic perspectives.

Authors:  M Ralli; R Rolesi; R Anzivino; R Turchetta; A R Fetoni
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-12       Impact factor: 2.124

4.  The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines.

Authors:  R Sirota; D Gibson; R Kohen
Journal:  Redox Biol       Date:  2016-12-07       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.